ExamPat

Bruce R Campell

USPTO Patent Examiner·Active 2012 to 2021

Bruce R Campell is a USPTO patent examiner who has handled 47 ex parte reexaminations between 2012 and 2021. These reexams concentrate in Chemistry & Materials, Life Sciences & Consumer, and Physics & Instruments. ExamPat indexes the full prosecution record for each of these cases, including office-action grounds, certificate outcomes, and downstream PTAB and federal-circuit decisions.

Filings by year

13
12
9
13
5
14
5
15
1
16
2
17
3
18
3
19
4
20
2
21

Technology mix

Chemistry & Materials28 (60%)
Life Sciences & Consumer16 (34%)
Physics & Instruments2 (4%)
Mechanical & Manufacturing1 (2%)

Compare against all examiners

Eight side-by-side metrics: case volume, pendency, OAs per reexam, rejection mix, SNQ denial rate, certification rate, and PTAB appeal rate, with a Δ column showing where this examiner runs higher or lower than the corpus.

  • Average and median pendency, both for this examiner and the corpus
  • Rejection basis split (102 / 103 / 112) head-to-head
  • Certification, SNQ denial, and PTAB appeal rates

Certificate outcome distribution

How this examiner's certificates split across the six possible outcomes: all claims confirmed, confirmed with amendment, confirmed with new claims, mixed, or all claims canceled. Includes share comparison to the corpus distribution.

  • Count and share for each of the six outcome buckets
  • Δ vs. corpus distribution in percentage points
  • Useful for setting realistic patent-owner expectations

Event-to-event timing

Median time for this examiner's cases at each prosecution stage — filing to first office action, filing to NIRC, and filing to certificate — with corpus comparison and sample size.

  • Median in months per transition
  • Side-by-side with the corpus median
  • n column showing how many of this examiner's cases completed each transition

Recent reexaminations (showing 25 of 47)

Control #FiledPatentTitlePendencyStatus
90/014,877Oct 6, 202110,920,222TREATING AND PREVENTING MICROBIAL INFECTIONS7 moClosed
90/014,738Apr 26, 202110,933,110SAFFRON EXTRACT AND ITS USE FOR THE PREVENTION OF MOOD DISORDERS RELATED TO DEPRESSION4 moClosed
90/014,586Oct 5, 20209,745,366Compositions and Methods for the Prevention of Microbial Infections9 moClosed
90/014,537Jun 25, 20207,968,112LIPIDS CONTAINING OMEGA-3 AND OMEGA-6 FATTY ACIDS10 moClosed
90/014,480Mar 24, 202010,383,903MEDICINAL COMPOSITION OF AMARANTH EXTRACT ORIGIN HAVING ENRICHED NITRATE CONTENT AND A METHOD OF PREPARING THE SAME12 moClosed
90/014,445Feb 3, 202010,400,260Protease-deficient mutants of Trichoderma for producing polypeptides12 moClosed
90/014,360Aug 6, 20197,777,098METHOD FOR PRODUCING UNSATURATED w-3-FATTY ACIDS IN TRANSGENIC ORGANISMS10 moClosed
90/014,311Jun 3, 20198,455,531Amino Acid Compositions15 moClosed
90/014,282Apr 9, 20197,625,558COMPOSITIONS AND METHODS OF TREATING TUMORS11 moClosed
90/014,230Nov 1, 20189,701,964ALTERING MICROBIAL POPULATIONS AND MODIFYING MICROBIOTA—Closed
90/014,184Aug 10, 20189,701,964ALTERING MICROBIAL POPULATIONS AND MODIFYING MICROBIOTA13 moClosed
90/014,116Mar 23, 20189,211,317METHOD OF USING PROUROKINASE IN FACILITATED PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION18 moClosed
90/014,026Oct 10, 20176,569,471METHOD FOR THE TREATMENT OF SYMPTOMS RELATED TO NORMAL HORMONAL VARIATIONS IN WOMEN18 moClosed
90/020,111Jul 27, 20179,227,230METHOD FOR OBTAINING SUBSTANTIALLY PURE HYBRID CEREAL SEED AND MACHINE FOR USE THEREOF28 moClosed
90/013,858Nov 3, 20168,558,055A GENETICALLY MODIFIED RAT COMPRISING A CYTOKINE GENE DISRUPTION AND EXHIBITING A GREATER SUSCEPTIBILITY TO A CYTOKINE-MEDIATED AUTOIMMUNE AND/OR INFLAMMATORY DISEASE27 moClosed
90/013,599Oct 1, 20158,900,639PROCESS FOR OBTAINING A RABBIT SKIN COMPRISING BIOLOGICAL ACTIVE SUBSTANCES30 moClosed
90/013,569Aug 21, 20157,494,974CARBOXYMETHYLATED CROSS-LINKED TETRAMERIC HEMOGLOBIN19 moClosed
90/013,467Mar 13, 20158,815,512METHOD FOR HIGH-THROUGHPUT AFLP-BASED POLYMORPHISM DETECTION12 moClosed
90/013,453Feb 17, 20155,648,477GENETICALLY ENGINEERED PLANT CELLS AND PLANTS EXHIBITING RESISTANCE TO GLUTAMINE SYNTHETASE INHIBITORS, DNA FRAGMENTS AND RECOMBINANTS FOR USE IN THE PRODUCTION OF SAID CELLS AND PLANTS71 moClosed
90/013,452Feb 17, 20155,561,236GENETICALLY ENGINEERED PLANT CELLS AND PLANTS EXHIBITING RESISTANCE TO GLUTAMINE SYNTHETASE INHIBITORS, DNA FRAGMENTS AND RECOMBINANTS FOR USE IN THE PRODUCTION OF SAID CELLS AND PLANTS71 moClosed
90/013,365Oct 15, 20148,623,603Full Cold-PCR Enrichment with Reference Blocking Sequence—Closed
90/013,355Sep 28, 20148,455,190Enrichment of a Target Sequence12 moClosed
90/013,216May 19, 20147,105,470HERBICIDAL COMPOSITIONS FOR TOLERANT OR RESISTANT SOYBEAN CROPS61 moClosed
90/020,068Apr 25, 20148,268,620OCT4 AND SOX2 WITH SV40 T ANTIGEN PRODUCE PLURIPOTENT STEM CELLS FROM PRIMATE SOMATIC CELLS14 moClosed
90/013,191Apr 24, 20146,579,899Composition for Treatment of Stress26 moClosed

Other USPTO reexam examiners

Get the full reexam analytics

Compare Bruce R Campell against the full corpus, see the certificate-outcome split, drill into event timing, filter the case list, and export. Free to sign up.